SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing intense volatility as investors weigh strong international growth and record revenue against concerns over brand momentum and competitive pressures ahead of its upcoming earnings report. The community is actively debating whether the recent share price slide near 52-week lows represents a deliberate institutional accumulation phase or a signal of fundamental weakness.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh strong financial results and aggressive growth targets against concerns over potential share offerings and broader software sector weakness. While many remain bullish on the company's AI-driven ad engine and cash flow, traders are actively discussing the stock's unpredictable price swings and high-stakes positioning ahead of upcoming catalyst events.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors react to a significant data center campus development in Thailand and an expanded partnership with Yotta, fueling speculation about long-term revenue potential and a possible short squeeze due to high short interest and a limited tradable float. The community is actively debating the legitimacy of these massive contract announcements and the company's ability to finance them, with many longs expressing high conviction in the stock's future as it attempts to break through key technical resistance levels.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant volatility and a sharp price correction as the market weighs competitive pressures from new AI agent technologies against the company's long-term infrastructure potential. Investors are actively debating whether this pullback represents a major fundamental breakdown or an overreaction that offers a strategic buying opportunity for the edge computing leader.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant leadership overhaul that replaced the former CEO with Chairman Kevin Tang, sparking optimism for a potential buyout. The community is actively debating the strategic implications of Tangs aggressive management style and the company's recent acquisition of Kezar Life Sciences as key catalysts for future value creation.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is heading into earnings with heightened volatility as investors weigh the company's path to profitability and potential AI-driven ad performance against concerns over executive leadership and stagnant North American user growth. While the community is divided between those betting on a turnaround through cost-cutting and potential buyout interest, others are actively preparing for typical post-earnings swings, debating if the stock is a deep-value opportunity or a long-term trap.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is currently trending following a report identifying the company as a key stealth supplier for Nvidia and Apple's advanced optical infrastructure, specifically regarding wafer-level optics for Co-Packaged Optics. The community is actively debating the sustainability of this price action, with some investors pointing to long-term growth in AI data center components, while skeptics caution against potential volatility and speculative hype.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant volatility as investors weigh strong fundamental performance and profitability against intense short-interest and broader macro uncertainty. While the community is actively discussing the stock's potential for a massive re-rating driven by its AI underwriting model and recent institutional wins, the price action remains heavily influenced by speculative trading and regional geopolitical concerns affecting the broader fintech sector.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to the company securing a $21 million purchase order for its SiCore cylindrical batteries from a major new electric mobility customer in China. Investors are closely monitoring the stock's price action as it attempts to maintain a sustained trading range above $18, which is a critical threshold for triggering the forced exercise of outstanding public warrants.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing significant volatility as market participants react to a resale registration filing that increases the number of shares available for trading. While some investors are concerned about potential supply overhang and the company's early-stage financials, the community is actively debating whether this sell-off is an overreaction or a structural reset for the quantum infrastructure play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

💥 Big Pharma Shake-Up: Torrent Acquires 49.18% in JB Pharma in ₹25,689 Cr Mega Deal 
🚨 India’s pharma sector just witnessed its second-largest deal ever. Torrent Pharmaceuticals($TORNTPHARM.NSE ) is set to acquire a controlling 49.18% stake in JB Chemicals &amp; Pharmaceuticals ($JBCHEPHARM.NSE JB Pharma) in a blockbuster transaction worth ₹25,689 crore (~$3.1 billion). 
 
🔎 KKR exits. Torrent enters. Markets react. 
 
🔁 The Deal Breakdown 
🧾 Stake Acquired: 
Torrent will buy 46.39% from KKR and up to 2.8% from JB Pharma’s employee trust — all at ₹1,600/share. 
 
📢 Open Offer Follows: 
Torrent will launch a mandatory open offer for another 26% at ₹1,639.18/share, valuing the open offer at ~₹6,843 crore. 
 
🔄 Merger Incoming: 
JB Pharma will merge into Torrent Pharma via share swap: 
🔁 100 JB shares = 51 Torrent shares 
 
📈 Why This Deal Matters 
💼 Strategic Synergy: 
JB Pharma brings a robust chronic therapies portfolio, strong prescription base, and a growing CDMO vertical. Torrent gains a ready platform to scale chronic and specialty businesses — both domestic and international. 
 
🏆 Industry Impact: 
This deal makes Torrent Pharma India’s 2nd most valued pharma company after Sun Pharma. 
💰 Combined revenue: ₹15,000+ crore 
📊 Pro forma EBITDA: ₹3,100+ crore 
 
🚀 Market Power Shift: 
Torrent gets access to 40+ brands ranked in the top 300, along with JB&#39;s international operations in the US, South Africa, and select emerging markets. 
 
📉 Market Reaction 
Stock Pre-Deal Price Open Offer Price 1-Day Move 
JB Pharma ₹1,800+ ₹1,639.18 🔻 ~6–7% 
Torrent Pharma ₹3,350–3,400 — 🔼 ~4% intraday 
 
💬 JB Pharma slipped as investors priced in the ~9% discount on open offer. Torrent rose on synergy bets and aggressive consolidation. 
 
🧠 Analyst Take 
“This is not just an acquisition — it’s Torrent placing a massive bet on chronic care scale and global CDMO ambitions. The merger with JB could unlock long-term EPS accretion, despite near-term overhang of integration and funding.” 
— Senior Pharma Analyst, Mumbai 
 
📌 Concerns: 
▪ Open offer discount disappointed retail shareholders 
▪ Integration complexity, margin dilution in short term 
 
📌 Upside: 
▪ Market leadership in chronic care 
▪ Expanded global footprint 
▪ Scale advantages in procurement &amp; R&amp;D 
 
🧮 The Bigger Picture 
🧬 Pharma Consolidation Era: 
As global players double down on India, M&amp;A momentum is rising. Scale, branded generics, and CDMO are the new battlegrounds. 
 
💡 KKR’s Exit: 
KKR’s exit reflects a full-cycle private equity play — buying at ₹400 in 2020, exiting at ₹1,600+ now. That’s a 4x return in under 5 years. 
 
💬 Final Word 
This deal marks a turning point in Indian pharma. Torrent isn’t just buying a company — it’s buying growth, globalisation, and market dominance. And with KKR stepping aside, the question now is: 
➡️ Can Torrent integrate fast and deliver shareholder alpha — or will the weight of the merger drag it down short term? 
 
✅ Stay tuned. The war for pharma dominance in India has just escalated.($NIFTY50.NSE )

Bala Yogesh

Rajni Murugan

Curious Trader

Anubhav Mishra

Yash Pathak

Rajesh Sharma

Harsh Jain

Yash Upadhyaya

Stocktwits India

Chaitanya Gupta

Suraj

Karthik P

Sunny Verma

$TORNTPHARM.NSE and $JBCHEPHARM.NSE among the trending tickers on the platform 💬 @finpire on the big pharma shake up 👇

StockTwits Web

Torrent Pharmaceuticals Ltd.

J.B. Chemicals & Pharmaceuticals Ltd.

Nifty 50 is trending as the market maintains a bullish recovery phase driven by strong domestic corporate earnings, which are currently overpowering global geopolitical anxieties surrounding the Strait of Hormuz. Investors are closely monitoring key technical levels, with community sentiment shifting toward a 'buy on dips' strategy while remaining cautious of potential volatility ahead of the upcoming earnings season.

💥 Big Pharma Shake-Up: Torrent Acquires 49.18% in JB Pharma in ₹25,689 Cr Mega Deal 
🚨 India’s pharma sector just witnessed its second-largest deal ever. Torrent Pharmaceuticals(

 ) is set to acquire a controlling 49.18% stake in JB Chemicals & Pharmaceuticals (

 JB Pharma) in a blockbuster transaction worth ₹25,689 crore (~$3.1 billion). 
 
🔎 KKR exits. Torrent enters. Markets react. 
 
🔁 The Deal Breakdown 
🧾 Stake Acquired: 
Torrent will buy 46.39% from KKR and up to 2.8% from JB Pharma’s employee trust — all at ₹1,600/share. 
 
📢 Open Offer Follows: 
Torrent will launch a mandatory open offer for another 26% at ₹1,639.18/share, valuing the open offer at ~₹6,843 crore. 
 
🔄 Merger Incoming: 
JB Pharma will merge into Torrent Pharma via share swap: 
🔁 100 JB shares = 51 Torrent shares 
 
📈 Why This Deal Matters 
💼 Strategic Synergy: 
JB Pharma brings a robust chronic therapies portfolio, strong prescription base, and a growing CDMO vertical. Torrent gains a ready platform to scale chronic and specialty businesses — both domestic and international. 
 
🏆 Industry Impact: 
This deal makes Torrent Pharma India’s 2nd most valued pharma company after Sun Pharma. 
💰 Combined revenue: ₹15,000+ crore 
📊 Pro forma EBITDA: ₹3,100+ crore 
 
🚀 Market Power Shift: 
Torrent gets access to 40+ brands ranked in the top 300, along with JB's international operations in the US, South Africa, and select emerging markets. 
 
📉 Market Reaction 
Stock Pre-Deal Price Open Offer Price 1-Day Move 
JB Pharma ₹1,800+ ₹1,639.18 🔻 ~6–7% 
Torrent Pharma ₹3,350–3,400 — 🔼 ~4% intraday 
 
💬 JB Pharma slipped as investors priced in the ~9% discount on open offer. Torrent rose on synergy bets and aggressive consolidation. 
 
🧠 Analyst Take 
“This is not just an acquisition — it’s Torrent placing a massive bet on chronic care scale and global CDMO ambitions. The merger with JB could unlock long-term EPS accretion, despite near-term overhang of integration and funding.” 
— Senior Pharma Analyst, Mumbai 
 
📌 Concerns: 
▪ Open offer discount disappointed retail shareholders 
▪ Integration complexity, margin dilution in short term 
 
📌 Upside: 
▪ Market leadership in chronic care 
▪ Expanded global footprint 
▪ Scale advantages in procurement & R&D 
 
🧮 The Bigger Picture 
🧬 Pharma Consolidation Era: 
As global players double down on India, M&A momentum is rising. Scale, branded generics, and CDMO are the new battlegrounds. 
 
💡 KKR’s Exit: 
KKR’s exit reflects a full-cycle private equity play — buying at ₹400 in 2020, exiting at ₹1,600+ now. That’s a 4x return in under 5 years. 
 
💬 Final Word 
This deal marks a turning point in Indian pharma. Torrent isn’t just buying a company — it’s buying growth, globalisation, and market dominance. And with KKR stepping aside, the question now is: 
➡️ Can Torrent integrate fast and deliver shareholder alpha — or will the weight of the merger drag it down short term? 
 
✅ Stay tuned. The war for pharma dominance in India has just escalated.(

This account has been verified as a SEBI Research Analyst (RA).

Verified SEBI RA Account

Sanyam Vaish

@finpire This is a bold consolidation move. $TORNTPHARM.NSE is clearly positioning itself as a serious challenger to $SUNPHARMA.NSE. If synergies play out as expected, this could unlock serious value over the next few years

Sun Pharmaceutical Industries Ltd.

 is clearly positioning itself as a serious challenger to 

. If synergies play out as expected, this could unlock serious value over the next few years

@finpire JB investors clearly disappointed with the open offer discount

 JB investors clearly disappointed with the open offer discount

@finpire  
Massive consolidation! Torrent is clearly positioning itself for long-term dominance. If they can execute the integration well, this could be a game changer.

  
Massive consolidation! Torrent is clearly positioning itself for long-term dominance. If they can execute the integration well, this could be a game changer.

@finpire  
Bold bet by Torrent. The synergy potential is big, but the near-term integration risks and margin pressure shouldn’t be underestimated.

  
Bold bet by Torrent. The synergy potential is big, but the near-term integration risks and margin pressure shouldn’t be underestimated.

@finpire looks like investors are not happy